Alector, Staying Private for Now, Pulls in $133M for Alzheimer’s R&D

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

AltPep, Backed by Section32 and Lilly, Gets $53M to Catch and Treat Early Alzheimer’s
AbbVie Shells Out $205M Upfront for Alector’s Antibodies Vs. Alzheimer’s